Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study
暂无分享,去创建一个
L. Coates | S. Siebert | S. Chakravarty | F. Lavie | M. Shawi | Warner Chen | S. Gao | G. Schett | M. Sharaf | M. Zimmermann
[1] O. Kehoe,et al. Psoriatic arthritis: review of potential biomarkers predicting response to TNF inhibitors , 2022, Inflammopharmacology.
[2] M. D. de Wit,et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021 , 2022, Nature Reviews Rheumatology.
[3] D. Gladman,et al. POS0005 BASELINE BIOMARKERS PREDICT BETTER RESPONSES TO DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, IN A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS , 2022, Annals of the Rheumatic Diseases.
[4] T. Sornasse,et al. OP0024 DIFFERENTIATION BETWEEN IL-6 AND IL-17 PATHWAY INHIBITION IN RELATIONSHIP WITH CLINICAL OUTCOMES IN NON-BIOLOGICAL DMARD-IR AND BIOLOGICAL DMARD-IR PSORIATIC ARTHRITIS PATIENTS TREATED WITH UPADACITINIB IN SELECT-PsA 1 AND SELECT-PsA 2 STUDIES , 2022, Annals of the Rheumatic Diseases.
[5] S. Nakayamada,et al. Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study , 2022, Arthritis Research & Therapy.
[6] L. Coates,et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS) , 2021, Annals of the Rheumatic Diseases.
[7] K. Leander,et al. Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials , 2021, RMD Open.
[8] S. Pennington,et al. Applying precision medicine to unmet clinical needs in psoriatic disease , 2020, Nature Reviews Rheumatology.
[9] A. Gottlieb,et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial , 2020, The Lancet.
[10] A. Deodhar,et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial , 2020, The Lancet.
[11] N. Wei,et al. Psoriatic Arthritis: What is Happening at the Joint? , 2019, Rheumatology and Therapy.
[12] A. Gottlieb,et al. Psoriatic arthritis for dermatologists , 2019, The Journal of dermatological treatment.
[13] D. Gladman,et al. Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab , 2019, The Journal of Rheumatology.
[14] A. Gottlieb,et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta‐analysis of observational and clinical studies , 2019, Journal of the American Academy of Dermatology.
[15] Jasvinder A. Singh,et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis , 2018, Arthritis care & research.
[16] S. Nakayamada,et al. OP0321 Precision medicine using different biological dmards based on characteristic phenotypes of peripheral t helper cells in psoriatic arthritis , 2018, Rheumatology.
[17] V. Chandran,et al. Exploring the Psoriatic Arthritis Proteome in Search of Novel Biomarkers , 2018, Proteomes.
[18] L. Coates,et al. Considerations for the definition of remission criteria in psoriatic arthritis. , 2017, Seminars in arthritis and rheumatism.
[19] D. Gladman,et al. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors , 2017, The New England journal of medicine.
[20] U. Wagner,et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial , 2017, The Lancet.
[21] J. Greenberg,et al. Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry , 2017, Clinical Rheumatology.
[22] P. Mease,et al. Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study , 2016, The Journal of Rheumatology.
[23] P. Mease. A short history of biological therapy for psoriatic arthritis. , 2015, Clinical and experimental rheumatology.
[24] S. Feldman,et al. The 5-point Investigator’s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials , 2015, The Journal of dermatological treatment.
[25] A. Gottlieb,et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, , 2014, Annals of the rheumatic diseases.
[26] D. Gladman,et al. Soluble Biomarkers Associated with Response to Treatment with Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis , 2013, The Journal of Rheumatology.
[27] A. Loft,et al. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry. , 2013, Arthritis and rheumatism.
[28] D. Gladman,et al. Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab , 2012, Annals of the rheumatic diseases.
[29] D. Gladman,et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project) , 2012, Annals of the rheumatic diseases.
[30] B. Bresnihan,et al. Acute-phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy. , 2012, Arthritis and rheumatism.
[31] A. Kavanaugh,et al. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis , 2010, Annals of the rheumatic diseases.
[32] D. Symmons,et al. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register , 2009, Arthritis research & therapy.
[33] M. Dougados,et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate , 2008, Annals of the rheumatic diseases.
[34] C. Sherbourne,et al. The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .
[35] F. Salaffi,et al. An observational prospective study on predictors of clinical response at six months in patients with active psoriatic arthritis treated with golimumab. , 2019, Clinical and experimental rheumatology.
[36] I. McInnes,et al. Serum CRP, IL-17A, and IL-17F levels are responsive to ustekinumab in psoriatic arthritis: lessons from the PSUMMIT study programme. , 2019, Arthritis & rheumatology.
[37] S. Rantapää Dahlqvist,et al. Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis? , 2009, Clinical and experimental rheumatology.
[38] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..
[39] Ware J.E.Jr.,et al. THE MOS 36- ITEM SHORT FORM HEALTH SURVEY (SF- 36) CONCEPTUAL FRAMEWORK AND ITEM SELECTION , 1992 .
[40] H. Holman,et al. Measurement of patient outcome in arthritis. , 1980, Arthritis and rheumatism.
[41] T Fredriksson,et al. Severe psoriasis--oral therapy with a new retinoid. , 1978, Dermatologica.
[42] D. Gladman,et al. Open Access Research Article Risk Factors for Radiographic Progression in Psoriatic Arthritis: Subanalysis of the Randomized Controlled Trial Adept , 2022 .